Are These Stocks Worth Considering? First Horizon National Corp (FHN), Cobalt International Energy, Inc. (CIE) and Galena Biopharma Inc (GALE)

Posted by admin May 20, 2015 0 Comment 2295 views

New York, NY – GDP INSIDER  –  05/20/2014.

This article discusses three companies: First Horizon National Corp (NYSE:FHN), Cobalt International Energy, Inc. (NYSE:CIE) and Galena Biopharma Inc (NASDAQ:GALE)

First Horizon National Corp (NYSE:FHN) continued its bullish run with the stock hitting a new all time high of $14.87 before falling back slightly to close up 0.82% or $0.12 yesterday at $14.82, on lower than average trading of 2.138 million shares, compared to its three month average trading volume of 2.19 million. The bank holding company has been doing well over the past one year with the stock gaining 32.82%, compared to the S&P 500 index which is up only 12.70% for the same period. The RSI of 64.04 indicates the stock is not overvalued at the current levels, the MFI of 63.91 shows the money is flowing in the right direction, making it a hold for now.

Can First Horizon National Corp Keep Gaining? Review The Financial With Our Free FHN Analysis.

Cobalt International Energy, Inc. (NYSE:CIE) reversed its recent upward trend yesterday with the stock declining 4.73% or $0.50 to finish the day at a closing price of $10.06 on light trading volume of 2.095 million compared with its three month average trading volume of 3.32 million. The exploration and production company has been steadily declining for the last 52 weeks, losing over 41% but has been starting to gain back some of these losses since the beginning of the year with the stock up by 13%. With its MACD diverging in a bearish direction and RSI of 46.33 the stock has plenty of room to fall further, worth holding on to but not a potential buy at this time.

Can Cobalt International Energy, Inc Surprise The Investors? Click Here For Free CIE Analysis.

Galena Biopharma Inc (NASDAQ:GALE) had a light trading yesterday with only 1.64 million shares changing hands compared to its three month average trading volume of 2.84 million. The stock traded between $1.27 and $1.32 before closing at its opening price of $1.31 with no change on the day. The oncology focused biotechnology company has been having a difficult year so far with the stock down over 14% year to date, underperforming the S&P 500 which is up only 3.35% over the same period. With one year price target estimate of $5.17 and quarterly revenue growth (yoy) of 27.30%, Galena Biopharma Inc has upside potential, hold.

Should You Invest In Galena Biopharma Inc Now? Take A Closer Look At Our Free GALE Analysis To Know More.

About Ultimate Stock Alerts covers NASDAQ and NYSE listed companies that are overlooked by Wall Street. Investors can choose to receive trading strategies via text message (SMS) or email. To receive free text message alerts text the word ULTIMATE to 555888 from your cell phone. For more information visit

Disclosure: is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit website, for complete risks and disclosures.

Write Your Comment